Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | GJB2 | P29033 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201783 | 0.90 | GBA1 (0.35) | GBA1MAPK1LMNACYP1A2THPO | |
| SCHEMBL4192378 | 0.85 | GBA1 (0.33) | GBA1 | |
| SCHEMBL12560682 | 0.83 | GBA1 (0.33) | GBA1 | |
| SCHEMBL12560698 | 0.83 | GBA1 (0.33) | GBA1 | |
| SCHEMBL12600389 | 0.83 | GBA1 (0.37) | GBA1GJB2CA1CA2CA9 | |
| SCHEMBL28276205 | 0.78 | MAPK1 (0.38) | GBA1MAPK1 | |
| SCHEMBL28274791 | 0.78 | MAPK1 (0.38) | GBA1MAPK1 | |
| SCHEMBL28276199 | 0.78 | MAPK1 (0.38) | GBA1MAPK1 | |
| SCHEMBL28274780 | 0.78 | MAPK1 (0.38) | GBA1MAPK1 | |
| SCHEMBL28066822 | 0.78 | GBA1 (0.41) | GBA1LMNACYP1A2THPOCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | GBA1 127/4885GJB2 4078/4885MAPK1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.